Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

Xiaolu Zhu, Feifei Tang, Wenjing Yu, Xiaosu Zhao, Yazhen Qin, Qian Jiang, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2023-180002

Published: 2023

Journal Articles

Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy

Xiaoshuai Zhang, Zongru Li, Yazhen Qin, Robert Peter Gale, Xiaojun Huang, Qian Jiang

Blood (2021) 138 (Supplement 1): 308.

https://doi.org/10.1182/blood-2021-150020

Published: 2021

Journal Articles

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

Jiang Qian, Dayu Shi, Zongru Li, Yazhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiaojun Huang

Blood (2021) 138 (Supplement 1): 311.

https://doi.org/10.1182/blood-2021-153065

Published: 2021

Journal Articles

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Jing Wang, MD, Jinsong Jia, Xiaohong Liu, Lizhong Gong, Shengye Lu, Yu Wang, Lanping Xu, Xiaohui Zhang, Chenhua Yan, Yueyun Lai, Xiaosu Zhao, PhD, Yazhen Qin, Guorui Ruan, Yingjun Chang, Hongxia Shi, Kaiyan Liu, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140977

Published: 2020

Journal Articles

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Wenbing Duan, Xiaohong Liu, Jinsong JIA, MDPhD, Jing Wang, MD, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaosu Zhao, PhD, Yazhen Qin, Hongxia Shi, Yingjun Chang, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141905

Published: 2020

Journal Articles

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, MD, Qian Jiang, MD

Blood (2019) 134 (Supplement_1): 2940.

https://doi.org/10.1182/blood-2019-130081

Published: 2019

Journal Articles

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Wenbing Duan, Jinsong Jia, Jing Wang, MD, Xiaohong Liu, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, MD, Lanping Xu, Yanrong Liu, Yazhen Qin, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 2616.

https://doi.org/10.1182/blood-2019-126938

Published: 2019

Journal Articles

Classifying AML Patients with Inv(16) into High-Risk and Low-Risk Relapsed Patients Based on Peritransplantation Minimal Residual Disease Determined By CBFÎ²/MYH11 Gene Expression

Xiaosu Zhao, Leqing Cao, Yazhen Qin, Xiaohui Zhang, Lanping Xu, Xiaojun Huang, Ying-Jun Chang

Blood (2018) 132 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2018-99-114261

Published: 2018

Journal Articles

Pre-Transplant Minimal Residual Disease Determined By Multiparameter Flow Cytometry Is Better Than RQ-PCR to Predict the Outcomes of Ph+ALL Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Xiaosu Zhao, Yanrong Liu, Yazhen Qin, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaojun Huang, Yingjun Chang, MD

Blood (2017) 130 (Supplement 1): 1998.

https://doi.org/10.1182/blood.V130.Suppl_1.1998.1998

Published: 2017

Journal Articles

The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaosu Zhao, Dr., Yan Hong, Yazhen Qin, Yingjun Chang, PhD, Xiaohui Zhang, Lanping Xu, Xiao Jun Huang, MD and, professor

Blood (2016) 128 (22): 5800.

https://doi.org/10.1182/blood.V128.22.5800.5800

Published: 2016

Journal Articles

The Initial Level of MLL-PTD Affects the Prognosis of Patients with Acute Myeloid Leukemia

Jun Kong, MD, Hao Jiang, MD, Yazhen Qin, Xiaosu Zhao, Dr., Hong-Hu Zhu, MD, Jinsong Jia, MD, Qian Jiang, MD, Jing Wang, MD, Ting Zhao, Xiao-Jun Huang

Blood (2016) 128 (22): 5241.

https://doi.org/10.1182/blood.V128.22.5241.5241

Published: 2016

Journal Articles

CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor

Xiao-Ying Qin, Yu Wang, Guo-Xuan Li, Yazhen Qin, Lan-Ping Xu, Fengrong Wang, Huan Chen, Wei Han, Jing-Zhi Wang, Xiao-Hui Zhang, Ying-Jun Chang, Kaiyan Liu, Zheng-Fan Jiang, Xiao-jun Huang

Blood (2015) 126 (23): 2006.

https://doi.org/10.1182/blood.V126.23.2006.2006

Published: 2015

Journal Articles

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia

Xiaosu Zhao, Yazhen Qin, Yanrong Liu, Lanping Xu, Xiao-Hui Zhang, Xiaojun Huang, Yingjun Chang

Blood (2015) 126 (23): 1970.

https://doi.org/10.1182/blood.V126.23.1970.1970

Published: 2015

Journal Articles

Minimal Residual Disease Monitoring By Quantitative RT-PCR In t (8; 21) AML Early After Allogeneic HSCT Can Predict Clinical Outcomes and Allow Further Risk Stratification

Yu Wang, Yanrong Liu, Yazhen Qin, Xiao-Jun Huang, MD, PhD

Blood (2013) 122 (21): 3386.

https://doi.org/10.1182/blood.V122.21.3386.3386

Published: 2013

Journal Articles

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Qian Jiang, Yazhen Qin, Yueyun Lai, Hao Jiang, Jing Wang, Hongxia Shi, MD, Xiaojun Huang, M.D Ph.D

Blood (2013) 122 (21): 5188.

https://doi.org/10.1182/blood.V122.21.5188.5188

Published: 2013

Journal Articles

Arsenic Trioxide Induces Apoptosis In Chronic Lymphocytic Leukemic Cells Through Down-Regulation Of Survivin Via The p53-Dependent Signaling Pathway

Xiaohui Zhang, Meng Lv, Qian Jiang, Honghu Zhu, Yazhen Qin, Xiaojun Huang, M.D Ph.D

Blood (2013) 122 (21): 5313.

https://doi.org/10.1182/blood.V122.21.5313.5313

Published: 2013

Journal Articles

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

Hao Jiang, Daihong Liu, Lanping Xu, Kaiyan Liu, Shanshan Chen, MD, Bin Jiang, MD, Qian Jiang, Huan Chen, Yuhong Chen, Wei Han, MD, Xiaohui Zhang, Yazhen Qin, Yueyun Lai, Yanrong Liu, MD, PhD, Xiaojun Huang

Blood (2013) 122 (21): 4035.

https://doi.org/10.1182/blood.V122.21.4035.4035

Published: 2013

Journal Articles

Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial

Honghu Zhu, PhD, Xiao-hui Zhang, MD, PhD, Yazhen Qin, Hao Jiang, MD, Dai-Hong Liu, MD, PhD, Huan Chen, Qian Jiang, MD, Jun-Yue Chai, Li-Ru Wang, Xiaojun Huang

Blood (2012) 120 (21): 139.

https://doi.org/10.1182/blood.V120.21.139.139

Published: 2012

Journal Articles

The PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes

Yazhen Qin, Honghu Zhu, PhD, Yan-rong Liu, MD, Ya-zhe Wang, Hong-Xia Shi, Yue-yun Lai, Lan-Ping Xu, MD, Daihong Liu, Xiaojun Huang

Blood (2012) 120 (21): 3853.

https://doi.org/10.1182/blood.V120.21.3853.3853

Published: 2012

Journal Articles

Combined Use of WT1 and Flow Cytometry Monitoring Can Promote Sensitivity of Predicting Relapse After Allogeneic HSCT without Affecting Specificity.

Xiaosu Zhao, Chenhua Yan, Daihong Liu, Lanping Xu, Yanrong Liu, Kaiyan Liu, MD, Yazhen Qin, Yu Wang, MD, Xiaojun Huang

Blood (2012) 120 (21): 3065.

https://doi.org/10.1182/blood.V120.21.3065.3065

Published: 2012

NARROW

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Classifying AML Patients with Inv(16) into High-Risk and Low-Risk Relapsed Patients Based on Peritransplantation Minimal Residual Disease Determined By CBFÎ²/MYH11 Gene Expression

Pre-Transplant Minimal Residual Disease Determined By Multiparameter Flow Cytometry Is Better Than RQ-PCR to Predict the Outcomes of Ph+ALL Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation

The Initial Level of MLL-PTD Affects the Prognosis of Patients with Acute Myeloid Leukemia

CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia

Minimal Residual Disease Monitoring By Quantitative RT-PCR In t (8; 21) AML Early After Allogeneic HSCT Can Predict Clinical Outcomes and Allow Further Risk Stratification

Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance

Arsenic Trioxide Induces Apoptosis In Chronic Lymphocytic Leukemic Cells Through Down-Regulation Of Survivin Via The p53-Dependent Signaling Pathway

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial

The PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes

Combined Use of WT1 and Flow Cytometry Monitoring Can Promote Sensitivity of Predicting Relapse After Allogeneic HSCT without Affecting Specificity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only